Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C21 InvestmentsCXXIF 31 Days Inventory is 73.86 as of Jun. 2026, which is 19% below its 10-year median of 90.64. GuruFocus rates CXXIF with a GF Score™ of 31/100 and a GF Value™ of $0.27 (Fairly Valued). The stock has 4 warning signs investors should review. Among 917 Drug Manufacturers companies, C21 Investments ranks better than 84.95% on this metric.
The historical rank and industry rank for C21 Investments's Days Inventory or its related term are showing as below:
CXXIF'
s Days Inventory Range Over the Past 10 Years
Min: 68.43 Med: 90.64 Max: 1326.04
Current: 84.23
During the past 13 years, C21 Investments's highest Days Inventory was 1326.04. The lowest was 68.43. And the median was 90.64.
CXXIF's Days Inventory is ranked better than 84.95% of 917
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs CXXIF: 84.23
C21 Investments's Days Inventory
increased
from Jun. 2025 (67.29) to Jun. 2026 (73.86).
It might indicate that C21 Investments's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
C21 Investments's Inventory Turnover for the
three
months ended in Jun. 2026 was 1.24.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
C21 Investments's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.55.
C21 Investments (OTCPK:CXXIF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
C21 Investments's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
C21 Investments's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
C21 Investments Days Inventory Related Terms
C21 Investments Days Inventory Historical Data
* Premium members only.
The historical data trend for C21 Investments's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, C21 Investments's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C21 Investments Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, C21 Investments's Days Inventory distribution charts can be found below:
* The bar in red indicates where C21 Investments's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C21 Investments (CXXIF) has a Days Inventory of 73.86 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on C21 Investments and its competitors. This is 19% below median its historical median of 90.64. Over the past decade, C21 Investments' Days Inventory has ranged from 68.43 to 1,326.04. According to the industry distribution chart, C21 Investments ranks #138 out of 917 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is C21 Investments' Days Inventory too high?
C21 Investments' current Days Inventory of 73.86 is 19% below median its 10-year median of 90.64. Over the past 10 years, this metric has ranged from a low of 68.43 to a high of 1,326.04. The Drug Manufacturers industry median Days Inventory is 164.48. C21 Investments' value of 73.86 is 55.1% below this industry median. Based on the distribution chart, C21 Investments ranks #138 out of 917 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, C21 Investments has a GF Score™ of 31/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C21 Investments' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, C21 Investments ranks #138 out of 917 companies for Days Inventory. This places C21 Investments in the top 15% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.48. C21 Investments' value of 73.86 is 55.1% below this benchmark. Historically, C21 Investments' own Days Inventory has ranged from 68.43 to 1,326.04 over the past decade. While the company's 10-year median is 90.64 vs. the industry median of 164.48, C21 Investments has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C21 Investments's current Days Inventory of 73.86 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on C21 Investments and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C21 Investments's current Days Inventory is 73.86, which is 19% below median its own 10-year median of 90.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C21 Investments stock overvalued right now?
Based on GuruFocus' analysis, C21 Investments (CXXIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.27, compared to a current price of $0.26 — trading 2% below its estimated fair value. The current Days Inventory is 73.86, which is 19% below median its 10-year median of 90.64 and 55.1% below the Drug Manufacturers industry median of 164.48. C21 Investments' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For C21 Investments (CXXIF), the current Days Inventory is 73.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C21 Investments (CXXIF) Overvalued in 2026?
Based on GuruFocus' analysis, C21 Investments stock appears to be undervalued.
The current stock price of $0.26 is trading 2% below its estimated GF Value™ of $0.27.
GuruFocus considers C21 Investments to be Fairly Valued.
Key valuation signals for CXXIF:
Days Inventory: 73.86 (19% below median its 10-year median of 90.64)
GF Value™: $0.27 vs. price of $0.26 (2% below fair value)
Industry Position: 55.1% below the Drug Manufacturers median (#138 of 917)
No single metric tells the full story. See the CXXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C21 Investments Inc is a vertically integrated cannabis company that cultivates, processes, distributes, and sells quality cannabis and hemp-derived consumer products in Nevada, U.S.A., and the United States. The Company is focused on value creation through the disciplined acquisition and integration of core retail, manufacturing, and distribution assets in strategic markets, leveraging industry retail revenues with high-growth potential and multi-market branded consumer packaged goods (CPG). The Company focuses on scalable opportunities in key markets through retail operational excellence, expanding its retail footprint through value-add acquisitions in existing markets, and branded CPG expansion through captive retail and wholesale channels.
31GF Score
Get the complete analysis for CXXIF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CXXIF has been successfully added to your 
